CoVPN 3003 JANSSEN
This trial is a Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
This study is being done to test the new experimental vaccine called Ad26.COV2.S. Doctors and scientists hope it will prevent or lessen the severity of disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This virus causes a disease called COVID-19. SARS-CoV-2 is passed from person to person primarily by small droplets from the nose or mouth when an infected person coughs, sneezes or speaks. Most people who are infected have mild disease such as cough and extreme tiredness, but some people have severe disease and have difficulty breathing and can even die from this disease. The new experimental vaccine being tested in this study is called Ad26.COV2.S. A vaccine helps to prevent disease by allowing the human body to form an immune response against what causes the disease, such as viruses or bacteria. This defensive response is a way your body fights infections. The immune response that Ad26.COV2.S causes is specific for SARS-COV-2. This study is being done to help determine if Ad26.COV2.S is safe for humans and causes an immune response that protects against infection with SARS-CoV-2.
- Study Identifier: 844093